Movement Alert｜10x Genomics, Inc. Falls 5.7% in Pre-Market Trading, Q2 Revenue Declines 12.7% YoY as Company Swings to Loss

Market Focus08-07

On August 7, 10x Genomics, Inc. fell 5.7% in pre-market trading, trading at $43.0/share, with turnover of $27,500. The decline was triggered by the company's Q2 earnings report released after the prior session's close, which revealed significant year-over-year deterioration in fundamentals despite headline beats on estimates.

Specifically, 10x Genomics, Inc. posted a Q2 loss of $0.14 per diluted share, swinging from earnings of $0.28 a year earlier. While the loss was narrower than the FactSet consensus estimate of a $0.24 loss, the reversal from profitability alarmed investors. Revenue for the quarter ended June 30 came in at $151.0 million, beating the $146.7 million estimate but declining 12.7% from $172.9 million in the year-ago period. The company raised its full-year guidance to $610 million to $630 million, up from prior guidance of $600 million to $625 million, compared with the analyst consensus of $613.7 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113948661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113948661","market":"us","top_or_hot":-1,"title":"Movement Alert｜10x Genomics, Inc. Falls 5.7% in Pre-Market Trading, Q2 Revenue Declines 12.7% YoY as Company Swings to Loss","media":"Market Focus","content":"<p><p>On August 7, 10x Genomics, Inc. fell 5.7% in pre-market trading, trading at $43.0/share, with turnover of $27,500. The decline was triggered by the company's Q2 earnings report released after the prior session's close, which revealed significant year-over-year deterioration in fundamentals despite headline beats on estimates.</p><p>Specifically, 10x Genomics, Inc. posted a Q2 loss of $0.14 per diluted share, swinging from earnings of $0.28 a year earlier. While the loss was narrower than the FactSet consensus estimate of a $0.24 loss, the reversal from profitability alarmed investors. Revenue for the quarter ended June 30 came in at $151.0 million, beating the $146.7 million estimate but declining 12.7% from $172.9 million in the year-ago period. The company raised its full-year guidance to $610 million to $630 million, up from prior guidance of $600 million to $625 million, compared with the analyst consensus of $613.7 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜10x Genomics, Inc. Falls 5.7% in Pre-Market Trading, Q2 Revenue Declines 12.7% YoY as Company Swings to Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜10x Genomics, Inc. Falls 5.7% in Pre-Market Trading, Q2 Revenue Declines 12.7% YoY as Company Swings to Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, 10x Genomics, Inc. fell 5.7% in pre-market trading, trading at $43.0/share, with turnover of $27,500. The decline was triggered by the company's Q2 earnings report released after the prior session's close, which revealed significant year-over-year deterioration in fundamentals despite headline beats on estimates.</p><p>Specifically, 10x Genomics, Inc. posted a Q2 loss of $0.14 per diluted share, swinging from earnings of $0.28 a year earlier. While the loss was narrower than the FactSet consensus estimate of a $0.24 loss, the reversal from profitability alarmed investors. Revenue for the quarter ended June 30 came in at $151.0 million, beating the $146.7 million estimate but declining 12.7% from $172.9 million in the year-ago period. The company raised its full-year guidance to $610 million to $630 million, up from prior guidance of $600 million to $625 million, compared with the analyst consensus of $613.7 million.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1113948661","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113948661","pubTimestamp":1786094610,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, 10x Genomics, Inc. fell 5.7% in pre-market trading, trading at $43.0/share, with turnover of $27,500. The decline was triggered by the company's Q2 earnings report released after the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"走势警报|10x Genomics, Inc. 在盘前交易中下跌 5.7%，第二季度收入同比下降 12.7%，公司陷入亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"On August 7, 10x Genomics, Inc. fell 5.7% in pre-market trading, trading at $43.0/share, with turnover of $27,500. The decline was triggered by the company's Q2 earnings report released after the prior session's close, which revealed significant year-over-year deterioration in fundamentals despite headline beats on estimates.Specifically, 10x Genomics, Inc. posted a Q2 loss of $0.14 per diluted share, swinging from earnings of $0.28 a year earlier. While the loss was narrower than the FactSet consensus estimate of a $0.24 loss, the reversal from profitability alarmed investors. Revenue for the quarter ended June 30 came in at $151.0 million, beating the $146.7 million estimate but declining 12.7% from $172.9 million in the year-ago period. The company raised its full-year guidance to $610 million to $630 million, up from prior guidance of $600 million to $625 million, compared with the analyst consensus of $613.7 million.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113948661","isCrawlerRequest":true}